CPRIT recently granted $93 million to 61 organizations and scientists, including many in Houston, to advance cancer research. Carter Smith/Courtesy of MD Anderson

Several prominent cancer researchers are coming to the Houston area thanks to $22 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

The biggest CPRIT recruitment grant — $6 million — went to genetics researcher Jean Gautier. Gautier, a professor of genetics and development at Columbia University’s Institute for Cancer Genetics, is joining the University of Texas MD Anderson Cancer Center to continue his research.

The website for Gautier’s lab at Columbia provides this explanation of his research:

“The main objective of our research is to better understand the molecular mechanisms responsible for the maintenance of genome stability. These controls are lost in cancer, which is characterized by genomic instability.”

Aside from his work as a professor, Gautier is co-leader of the Herbert Irving Comprehensive Cancer Center’s Cancer Genomics and Epigenomics Program at Columbia.

Other recipients of CPRIT recruitment grants include:

  • $2 million to recruit Xun Sun from the Scripps Research Institute to the University of Texas Medical Branch at Galveston.
  • $2 million to recruit Mingqi Han from the University of California, Los Angeles to MD Anderson.
  • $2 million to recruit Matthew Jones from Stanford University to MD Anderson.
  • $2 million to recruit Linna An from the University of Washington to Rice University.
  • $2 million to recruit Alissa Greenwald from the Weizmann Institute of Science to MD Anderson.
  • $2 million to recruit Niladri Sinha from Johns Hopkins University to the Baylor College of Medicine.
  • $2 million for Luigi Perelli to stay at MD Anderson so he can be put on a tenure track and set up a research lab.
  • $2 million for Benjamin Schrank to stay at MD Anderson so he can be put on a tenure track and set up a research lab.

Over $20.2 million in academic research grants were awarded to researchers at:

  • Baylor College of Medicine
  • Houston Methodist Research Institute
  • Rice University
  • Texas Southern University
  • University of Houston
  • University of Texas Health Science Center at Houston
  • University of Texas MD Anderson Cancer Center
  • University of Texas Medical Branch at Galveston

In addition, nearly $4.45 million in cancer prevention grants were awarded to one researcher at the University of Texas Medical Branch at Galveston and another at Texas Southern University.

Also, five Houston businesses benefited from CPRIT grants for product development research:

  • Allterum Therapeutics, $2,999,996
  • CTMC, $1,342,178
  • Instapath, $900,000
  • Prana Surgical, $900,000
  • InformAI, $465,188

“Texas is a national leader in the fight against cancer,” said Kristen Pauling Doyle, CPRIT’s CEO. “We can measure the return on investment from CPRIT grants … not only in the economic benefits flowing from increased financial activity and jobs in the state, but more importantly in the cancers avoided, detected early, and treated successfully. Thanks to the Legislature’s vision, this commitment is saving lives.”

Overall, CPRIT approved 61 grants totaling more than $93 million in this recent round of funding.

Houston hospitals and universities have been granted millions from the CPRIT to advance cancer research and bring leading scientists to the state. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau.

Texas institute grants $12M to bring leading cancer researchers to Houston

cha-ching

Rice University has recruited a prominent Swedish cancer researcher thanks to a $6 million grant from the Cancer Prevention and Research Institute of Texas.

It’s among $68 million in research grants recently awarded by the state agency, and six recruitment grants totaling $16 million to bring leading cancer researchers to Texas.

A news release from the Cancer Prevention and Research Institute of Texas (CPRIT) describes Pernilla Wittung-Stafshede of the Chalmers University of Technology in Gothenburg, Sweden, as “an accomplished and highly gifted biophysical scientist tackling complicated biological questions regarding the role of metals and metal dysregulation in various diseases. She pioneered a new research field around the role of metal ions in the folding and function of metalloproteins.”

Metalloproteins account for nearly half of all proteins in biology, according to the National Institutes of Health. They “catalyze some of the most difficult and yet important functions in [nature], such as photosynthesis and water oxidation,” the federal agency says.

Wittung-Stafshede, a professor of chemical biology and life sciences at Chalmers, is a former professor at Rice.

Aside from the money for Wittung-Stafshede, Houston recruitment grants also went to:

  • University of Texas M.D. Anderson Cancer Center: $2 million to recruit Rosalie Griffin of the Mayo Clinic
  • Baylor College of Medicine: $2 million to recruit Dr. Nipun Verma of the Yale University School of Medicine
  • Baylor College of Medicine: $2 million to recruit Xin “Daniel” Gao of Harvard University and the Massachusetts Institute of Technology

In Houston, cancer research grants were given to:

  • Baylor College of Medicine: $7.8 million
  • M.D. Anderson Cancer Center: $20.7 million
  • Rice University: $ 1 million
  • University of Houston: $1.2 million
  • University of Texas Health Science Center at Houston: $4.5 million

“The awards … represent the depth and diversity of CPRIT funding for cancer research in Texas,” says Kristen Doyle, CEO of CPRIT. “These grants develop new approaches to preventing, diagnosing, treating, and surviving cancer for all Texans.”

See the full list of awards here.

Several Houston institutions scored funding from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

German biotech co. to relocate to Houston thanks to $4.75M CPRIT grant

money moves

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

  • $2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
  • $2 million to recruit Xufeng Chen from New York University to MD Anderson.
  • $2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

  • $9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
  • $2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
  • $1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
  • $1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
  • $449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

MD Anderson Cancer Center received $3 million to establish a new genomics research hub. Photo by F. Carter Smith/Courtesy of MD Anderson

Houston hospital to establish genomics research hub as part of CPRIT's $60M round of grants

coming soon

Houston’s University of Texas MD Anderson Cancer Center will create a genomics research hub thanks to a nearly $3 million award from the Cancer Prevention and Research Institute of Texas, or CPRIT.

“This groundbreaking facility will have a profound impact on cancer research, and improving the diagnosis and treatment of cancer patients in Texas,” says CPRIT.

CPRIT gave the monetary award to Nicholas Navin, a professor at MD Anderson and at the biomedical sciences school within the University of Texas Health Science Center at Houston (UTHealth Houston).

The new facility will specialize in advanced spatial genomics, which creates a three-dimensional “atlas” that’s been dubbed “the Google Map of the human body,” according to CPRIT.

“Spatial genomics is an exciting new field that allows cancer researchers to directly connect the images of cells and their tissue structures with genomic data while preserving the spatial context,” CPRIT explains. “This provides the researchers with the ability to see exactly where distinct types of cells are located within a tumor, and determine the genes and proteins they are expressing.”

Until recently, most genomic technologies such as DNA and RNA sequencing required scientists to “grind up” tumor tissues to extract molecules for analysis, according to CPRIT.

“This process means losing the complex composition of the different cell types and their spatial arrangement within the tumor, which makes it difficult to understand the complex environment of cancer cells,” the institute adds.

MD Anderson’s new genomics hub will feature tissue processing, slide imaging, spatial genomics technologies, and spatial data analysis methods for cancer researchers within the Texas Medical Center and around the state.

In other CPRIT funding news, three local medical institutions received a total of $8 million for recruitment of four cancer researchers.

MD Anderson received half of the $8 million from CPRIT. The money will go toward bring aboard:

  • Hojong Yoon. Yoon, recipient of a $2 million scholar recruitment award, is a postdoctoral student at the Cambridge, Massachusetts-based Broad Institute. The institute, affiliated with Harvard University and MIT, is a research organization. Yoon’s research focuses on targeted cancer therapy.
  • Marianna Trakala. Trakala, recipient of a $2 million scholar recruitment award, is a postdoctoral researcher at MIT’s Koch Institute for Integrative Cancer Research. She is studying how small conditional RNA (scRNA) causes a response that triggers activation of the immune system and elimination of cancer cells from tissue.

The Baylor College of Medicine and the University of Texas Health Science Center at Houston (UTHealth Houston) each received one $2 million scholar recruitment award:

  • Louai Labanieh, a postdoctoral researcher at Stanford University’s Parker Institute for Cancer Immunotherapy, is joining the Baylor College of Medicine. Labanieh’s research involves engineering next-generation cells to improve cancer immunotherapy.
  • Yanjun Sun, a neuroscientist who is a postdoctoral scholar at Stanford, is joining UTHealth Houston.

In all, CPRIT recently doled out more than $60 million for cancer-fighting efforts around the state. Aside from the Baylor College of Medicine, MD Anderson, and UTHealth Houston, Rice University and Texas Southern University received CPRIT funding.

“By supporting the vital core facilities that researchers need, funding groundbreaking research, and deepening the bench of clinical trial investigators, CPRIT is fulfilling the promise central to our mission: We are helping Texans conquer cancer,” says Kristen Doyle, CEO of CPRIT.

The grants, which are between $2 million to $6 million each, are earmarked for recruitment of prominent researchers. Photo via Getty Images

Houston health care institutions receive $22M to attract top recruits

coming to Hou

Houston’s Baylor College of Medicine has received a total of $12 million in grants from the Cancer Prevention & Research Institute of Texas to attract two prominent researchers.

The two grants, which are $6 million each, are earmarked for recruitment of Thomas Milner and Radek Skoda. The Cancer Prevention & Research Institute of Texas (CPRIT) announced the grants May 14.

Milner, an expert in photomedicine for surgery and diagnostics, is a professor of surgery and biomedical engineering at the Beckman Laser Institute & Medical Clinic at the University of California, Irvine and the university’s Chao Family Comprehensive Cancer Center

In 2013, Milner was named Inventor of the Year by the University of Texas at Austin. At the time, he was a professor of biomedical engineering at UT. One of his major achievements is co-development of the MasSpec Pen, a handheld device that identifies cancerous tissue within 10 seconds during surgical procedures.

Skoda is a professor of molecular medicine in the Department of Biomedicine at the University of Basel and the University Hospital Basel, both in Switzerland. He specializes in developing treatments for myeloproliferative neoplasms, which are a group of blood diseases including leukemia.

Other recruitment grants provided by the institute to Houston-area organizations are:

  • $4 million for recruitment of Susan Bullman to the University of Texas M.D. Anderson Cancer Center. She was an assistant professor at Seattle’s Fred Hutchinson Cancer Center, where she studied the connection between microbes and cancer.
  • $4 million for recruitment of Oren Rom to the University of Texas M.D. Anderson Cancer Center. Rom is an assistant professor of pathology and translational pathobiology at Louisiana State University Shreveport.
  • Nearly $2 million for recruitment of Lauren Hagler to conduct RNA cancer biology at Texas A&M University. She is a postdoctoral scholar in biochemistry at Stanford University.

The institute also awarded grants to five companies in the Houston area:

  • $4.7 million to 7 Hills Pharma for development of immunotherapies to treat cancer and prevent infectious diseases.
  • $4.5 million to Indapta Therapeutics for the Phase 1 trial of a cell therapy for treatment of multiple myeloma and non-Hodgkin’s lymphoma.
  • $2.75 million to Bectas Therapeutics for development of antibodies and biomarkers to overcome a type of resistance T-cell checkpoint therapy.
  • $2.69 million to MS Pen Technologies for development of technology that differentiates between normal tissue and cancerous tissue during surgery.
  • $2.58 million to Crossbridge Bio for development of an antibody-drug combination to treat certain solid tumors.
The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia, one of the most common childhood cancers. Photo via Getty Images

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup funding surpasses $1B in 2025 despite national slowdown

by the numbers

Houston-area startups raised more than $1 billion in venture capital during the first half of 2025 — almost double the haul for the first half of last year.

According to the new PitchBook-NCVA Venture Monitor, Houston-area startups raised $417.2 million in the second quarter of this year, compared with $281 million during the same period last year. In the first quarter of 2025, local startups collected $607.5 million in venture capital, compared with $281 million during the same period a year earlier.

Based on those figures, Houston-area startups picked up slightly over $1 billion in VC during the first half of this year, compared with $535 million in the first half of 2024.

Nationally, startups gained almost $70 billion in VC in the second quarter, down 25 percent from the same period a year ago, the PitchBook-NCVA Venture Monitor says.

Nizar Tarhuni, executive vice president of research and market intelligence at PitchBook, explained that “the VC landscape continues to navigate a fragile recovery” and is constrained by economic uncertainty.

However, startups in certain sectors are poised to attract a great deal of attention and venture capital over the next several years, according to the report.

“Companies operating in AI, national security, defense tech, fintech, and crypto — sectors aligned with the administration’s priorities — are attracting disproportionately more investor interest, and this trend will likely continue throughout President Donald Trump’s term,” the report says.

The AI sector accounted for 64 percent of VC deal value in the first half of 2025, according to the report.

Houston space companies land $150M NASA contract for vehicles and robots

space simulations

Houston-based MacLean Engineering and Applied Technology Services LLC, known as METECS, has received a five-year contract from NASA to develop simulations and software services for space-based vehicles and robots, with a maximum value of $150 million.

Two other Houston-area companies, Tietronix Software Inc. and Vedo Systems LLC, were assigned as subcontractors for the award.

"This award is a strong testament to NASA’s continued trust in the quality of our work and their confidence in our ongoing support of the human spaceflight program," John MacLean, president of METECS said in a release.

According to NASA, the awardees are tasked with providing:

  • Simulation and software services for space-based vehicle models and robotic manipulator systems
  • Human biomechanical representations for analysis and development of countermeasure devices
  • Guidance, navigation, and control of space-based vehicles for all flight phases
  • Space-based vehicle on-board computer systems simulations of flight software systems
  • Astronomical object surface interaction simulation of space-based vehicles
  • Graphics support for simulation visualization and engineering analysis
  • Ground-based and onboarding systems to support human-in-the-loop training

The contract is called Simulations and Advanced Software Services II (SASS II), and begins in October. This is the second time METECS has received the SASS award. The first also ran for five years and launched in 2020, according to USASpending.gov.

METECS specializes in simulation, software, robotics and systems analysis. It has previously supported NASA programs, including Orion, EHP, HLS, Lunar Gateway and Artemis. It also serves the energy, agriculture, education and construction sectors.

Tietronix Software has won numerous awards from NASA. Most recently, it won the NASA JSC Exceptional Software Award (2017). Some of its other customers include Houston Independent School District, Baylor College of Medicine, DARPA and Houston Methodist.

Video Systems offers software for implementing human-rated, AI and autonomous systems, as well as engineering services to address the needs of spaceflight and defense. The company has previously worked with NASA and METECS, as well as Axiom Space and defense contractor Lockheed Martin.

The three companies are headquartered near NASA’s Johnson Space Center in Houston.